Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lo Prinzi Federica, Salani Francesca, Rimini Margherita, Rizzato Mario Domenico, Antonuzzo Lorenzo, Camera Silvia, Satake Tomoyuki, Vandeputte Hanne, Vivaldi Caterina, Pressiani Tiziana, Lucchetti Jessica, Kim Jin Won, Abidoye Oluseyi, Rapposelli Ilario Giovanni, Tamberi Stefano, Finkelmeier Fabian, Giordano Guido, Pircher Chiara, Chon Hong Jae, Braconi Chiara, Pastorino Alessandro, Castet Florian, Tamburini Emiliano, Yoo Changhoon, Parisi Alessandro, Diana Anna, Scartozzi Mario, Prager Gerald W, Avallone Antonio, Schirripa Marta, Kim Il Hwan, Perkhofer Lukas, Oneda Ester, Verrico Monica, Adeva Jorge, Chan Stephen L, Spinelli Gian Paolo, Personeni Nicola, Garajova Ingrid, Rodriquenz Maria Grazia, Leo Silvana, Melo Alvim Cecilia, Roque Ricardo, Fornaro Lorenzo, De Rosa Antonio, Lavacchi Daniele, Rossari Federico, Ikeda Masafumi, Dekervel Jeroen, Niger Monica, Balsano Rita, Tonini Giuseppe, Kang Minsu, Bekaii-Saab Tanios, Viola Massimo Giuseppe, Silvestro Lucrezia, Esposito Luca, Boccaccino Alessandra, Himmelsbach Vera, Landriscina Matteo, Ahcene Djaballah Selma, Zanuso Valentina, Masi Gianluca, Lonardi Sara, Rimassa Lorenza, Casadei-Gardini Andrea
Аннотация
METHODS: The study cohort included patients with BTC who underwent surgery on the primary tumor, experienced disease recurrence occurring ≤6 months or >6 months after surgery or after the end of adjuvant therapy and started CGD. The primary objectives were overall survival (OS) and progression free survival (PFS).
RESULTS: A total of 178 patients were enrolled. No significant differences were observed between early and late relapse groups in OS (23.4 months vs not reached; HR 1.26; 95% CI, 0.67-2.37; P = .45) and PFS [7.0 months vs 9.8 months; HR 1.3(95% CI, 0.9-2.1) P = .13]. Overall response rate and disease control rate (P = .33 and P = .62) were comparable between the 2 groups, as the overall safety profile. In addition, we compared survival outcomes between the selected population and a historical cohort of patients with BTC treated with cisplatin-gemcitabine (CG) and found that despite the absence of statistical significance, CGD showed an outcome trend compared with CG regardless of the time of recurrence after surgery or adjuvant chemotherapy [(CG ≤ 6 vs CGD ≤ 6 months: HR 0.59, 95%CI, 0.35-1.01, P = .05; HR 0.70; 95%CI, 0.46-1.06, P = .09, OS and PFS, respectively) and (CG > 6 vs. CGD > 6 months: HR 0.50; 95%CI, 0.29-0.88, P = 0.0165; HR 0.54; 95%CI, 0.35-0.84, P = .0068, OS and PFS, respectively)].
CONCLUSION: Our analysis suggests that CGD retains its efficacy independently of the timing of relapse after surgery or completion of adjuvant treatment in patients with advanced BTC.